China Resources Double-Crane Pharmaceutical Co Ltd Financial Flexibility Index
China Resources Double-Crane Pharmaceutical Co Ltd financial flexibility index. China Resources Double-Crane Pharmaceutical Co Ltd (600062) has a Financial Flexibility Index of 0.14x as of September 2025. Free cash flow of CN¥680.18 Million (operating CF CN¥487.90 Million minus capex CN¥192.28 Million) represents 0% of total liabilities (CN¥4.85 Billion). Explore China Resources Double-Crane Pharmaceuti (600062) reinvestment ratio to see what proportion of operating cash flow is directed to capital expenditures.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of China Resources Double-Crane Pharmaceutical Co Ltd (1998–2024)
Financial flexibility index of China Resources Double-Crane Pharmaceutical Co Ltd from 1998 to 2024. Historical Financial Flexibility Index trend for China Resources Double-Crane Pharmaceutical Co Ltd across 27 annual periods. Check 600062 cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
China Resources Double-Crane Pharmaceutical Co Ltd Financial Flexibility Index by Year (1998–2024)
China Resources Double-Crane Pharmaceutical Co Ltd financial flexibility index by year from 1998 to 2024. Year-by-year free cash flow to debt coverage for China Resources Double-Crane Pharmaceutical Co Ltd. For the full cash flow conversion analysis, see China Resources Double-Crane Pharmaceuti (600062) cash flow conversion.
| Year | Flexibility Index | Free Cash Flow (CNY) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | 0.44x | CN¥2.46 Billion | CN¥1.83 Billion | CN¥5.57 Billion | ▼ -29.0% |
| 2023 | 0.62x | CN¥2.27 Billion | CN¥1.65 Billion | CN¥3.64 Billion | ▲ +25.0% |
| 2022 | 0.50x | CN¥1.87 Billion | CN¥1.34 Billion | CN¥3.75 Billion | ▼ -13.1% |
| 2021 | 0.57x | CN¥1.83 Billion | CN¥1.34 Billion | CN¥3.20 Billion | ▲ +1.9% |
| 2020 | 0.56x | CN¥1.71 Billion | CN¥1.36 Billion | CN¥3.04 Billion | ▼ -13.1% |
| 2019 | 0.65x | CN¥1.68 Billion | CN¥1.44 Billion | CN¥2.60 Billion | ▼ -8.7% |
| 2018 | 0.71x | CN¥1.70 Billion | CN¥1.47 Billion | CN¥2.40 Billion | ▼ -16.1% |
| 2017 | 0.84x | CN¥1.34 Billion | CN¥1.19 Billion | CN¥1.59 Billion | ▲ +15.3% |
| 2016 | 0.73x | CN¥881.29 Million | CN¥771.25 Million | CN¥1.20 Billion | ▲ +11.9% |
| 2015 | 0.65x | CN¥869.83 Million | CN¥701.35 Million | CN¥1.33 Billion | ▼ -28.9% |
| 2014 | 0.92x | CN¥860.76 Million | CN¥718.38 Million | CN¥934.93 Million | ▲ +38.0% |
| 2013 | 0.67x | CN¥763.92 Million | CN¥546.24 Million | CN¥1.14 Billion | ▲ +94.5% |
| 2012 | 0.34x | CN¥617.94 Million | CN¥396.05 Million | CN¥1.80 Billion | ▼ -30.0% |
| 2011 | 0.49x | CN¥850.31 Million | CN¥511.53 Million | CN¥1.73 Billion | ▼ -28.7% |
| 2010 | 0.69x | CN¥879.85 Million | CN¥509.67 Million | CN¥1.28 Billion | ▲ +29.6% |
| 2009 | 0.53x | CN¥627.17 Million | CN¥342.01 Million | CN¥1.18 Billion | ▼ -7.4% |
| 2008 | 0.57x | CN¥640.91 Million | CN¥331.71 Million | CN¥1.12 Billion | ▲ +101.8% |
| 2007 | 0.28x | CN¥371.63 Million | CN¥235.46 Million | CN¥1.31 Billion | ▼ -24.5% |
| 2006 | 0.38x | CN¥475.37 Million | CN¥303.71 Million | CN¥1.26 Billion | ▲ +164.0% |
| 2005 | 0.14x | CN¥266.91 Million | CN¥139.78 Million | CN¥1.87 Billion | ▼ -49.7% |
| 2004 | 0.28x | CN¥650.55 Million | CN¥453.72 Million | CN¥2.30 Billion | ▲ +37.1% |
| 2003 | 0.21x | CN¥524.92 Million | CN¥148.94 Million | CN¥2.54 Billion | ▲ +5.8% |
| 2002 | 0.20x | CN¥392.62 Million | CN¥140.63 Million | CN¥2.01 Billion | ▼ -22.5% |
| 2001 | 0.25x | CN¥316.60 Million | CN¥141.01 Million | CN¥1.26 Billion | ▼ -39.0% |
| 2000 | 0.41x | CN¥259.63 Million | CN¥172.81 Million | CN¥628.89 Million | ▼ -2.9% |
| 1999 | 0.43x | CN¥201.40 Million | CN¥131.54 Million | CN¥473.60 Million | ▼ -27.2% |
| 1998 | 0.58x | CN¥116.51 Million | CN¥-13.78 Million | CN¥199.57 Million | — |